Kiniksa Pharmaceuticals International (KNSA) Cash from Investing Activities Growth (1y) (2018 - 2026)
Kiniksa Pharmaceuticals International (KNSA) Cash from Investing Activities Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.14 Bn | 5.61 Bn | 220.03 Mn | -1,794.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,794.93% |
| Mar 31, 2026 | 38.08% |
| Dec 31, 2025 | -208.46% |
| Sep 30, 2025 | -888.58% |
| Jun 30, 2025 | 91.70% |
| Mar 31, 2025 | -301.93% |
| Dec 31, 2024 | 538.38% |
| Sep 30, 2024 | 48.29% |
| Jun 30, 2024 | -231.70% |
| Mar 31, 2024 | 167.31% |
| Dec 31, 2023 | 65.09% |
| Sep 30, 2023 | -164.48% |
| Jun 30, 2023 | -7.14% |
| Mar 31, 2023 | -66.88% |
| Dec 31, 2022 | 14.75% |
| Sep 30, 2022 | -60.21% |
| Jun 30, 2022 | -55.50% |
| Mar 31, 2022 | -150.68% |
| Dec 31, 2021 | -172.90% |
| Sep 30, 2021 | 131.97% |